alone in HR positive MBC patients.29, 30 A recently reported randomized phase III trial in postmenopausal women with hormone LY294002 154447-36-6 receptor-positive MBC aromatase not stero Tue letrozole 2.5 mg once t Possible or placebo plus lapatinib 1500 mg once t Possible as the first line therapy.18 Before neoadjuvant / adjuvant anti-estrogen, Was wel t, there were adjuvant aromatase inhibitors and trastuzumab when given � 2 months before the trial. Superior in women with HR positive HER2-positive disease after a median follow-up of 1.8 years, the combination of lapatinib letrozole letrozole alone, with median progression-free survival time of 8.2 and 3.0 months. Lapatinib has also been improved CBR letrozole.
There was no significant improvement in overall survival, but less than 50% of OS events took place at the time of reporting. Patients with hormone receptor-positive disease had HER2-negative, no improvement in progression-free survival. In this subgroup of patients who had endocrine treatment � �e done or not again U endocrine therapy for BI 2536 � Months had no additional keeping benefits from the combination of letrozole alone. In contrast, in women with � Months after discontinuation of adjuvant tamoxifen, a non-significant trend towards l Ngere PFS taken note of. In this group, adjuvant tamoxifen was administered for a median of 2.8 years, which is resistance to tamoxifen, and the median time since the judgment was only one month. So in the HER2-negative Bev is Lkerung can add to the receptor EGFR/HER2 advantages and can be a R Main contribution to the growth factor signaling reflect.
Lack of PR expression has been proposed as a replacement for endocrine resistance. This study supports the use and management of cancer research Lapatinib 2010:2 19 Dovepress foreground MBC you submit your manuscript | dovepress.com Dovepress combination therapy of lapatinib and letrozole in patients with hormone receptor-positive, HER2 positive only in the letrozole. HER2-positive patients in the HR-negative, no clinically significant results reached statistical significance, but other studies on the evaluation of biomarkers and stratification on the basis of the reactivity of t before hormone therapy can find a subgroup with advantage.
R The lapatinib in CNS metastases lapatinib first line, either alone or in combination with radiation therapy, surgery or other cancer treatment for patients with CNS metastases has not been explored fa It interested. Observations of the Phase II monotherapy were 6 patients with CNS disease stable at baseline, one patient CNS disease was the only site of disease progression, had 3 patients progression Systemic only one patient died before progression documented and established a patient progression-free at the time of discontinuation.13 Although data is lacking at present, the first line, k can CNS activity t of lapatinib, a force in its definition of its place in therapy. The CNS is a place for education and relapsed patients with HER2-positive breast cancer. This can penetrate the natural tendency of the HER2-positive tumors on the central nervous system present, improves the contr The systemic trastuzumab with an L Ngeren survival time of the development of CNS metastases and / or CNS as a sanctuary site for metastases due to poor penetrance of trastuzumab through the blood-brain barrier. Monoclonal Be prevented from entering the body